Jan Fourie

1.8k total citations
13 papers, 939 citations indexed

About

Jan Fourie is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Jan Fourie has authored 13 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 12 papers in Virology and 1 paper in Epidemiology. Recurrent topics in Jan Fourie's work include HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (9 papers). Jan Fourie is often cited by papers focused on HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (9 papers). Jan Fourie collaborates with scholars based in United States, Thailand and Argentina. Jan Fourie's co-authors include Jaime Andrade‐Villanueva, Bonaventura Clotet, Katia Boven, Simon Vanveggel, Margaret Johnson, L Rimsky, Hao Wu, Herta Crauwels, Calvin Cohen and Éric Lefebvre and has published in prestigious journals such as The Lancet, Antimicrobial Agents and Chemotherapy and AIDS.

In The Last Decade

Jan Fourie

13 papers receiving 905 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Fourie United States 10 882 678 190 149 62 13 939
Joseph J. Eron United States 16 978 1.1× 734 1.1× 297 1.6× 186 1.2× 61 1.0× 29 1.1k
José Valdez Madruga Brazil 7 775 0.9× 600 0.9× 154 0.8× 181 1.2× 58 0.9× 11 829
Catherine Granier United Kingdom 8 908 1.0× 699 1.0× 267 1.4× 141 0.9× 45 0.7× 10 976
Dan Duiculescu Romania 11 805 0.9× 628 0.9× 219 1.2× 225 1.5× 42 0.7× 22 949
Christopher Stone United States 10 672 0.8× 550 0.8× 108 0.6× 147 1.0× 40 0.6× 18 733
Kati Vandermeulen Belgium 12 651 0.7× 480 0.7× 177 0.9× 133 0.9× 35 0.6× 19 713
Ellen Koenig United States 12 760 0.9× 533 0.8× 275 1.4× 145 1.0× 49 0.8× 23 822
Akil Jackson United Kingdom 20 686 0.8× 525 0.8× 228 1.2× 197 1.3× 59 1.0× 52 888
Debbie Hagins United States 11 597 0.7× 447 0.7× 191 1.0× 94 0.6× 32 0.5× 28 660
Antonio Antela Spain 6 732 0.8× 558 0.8× 207 1.1× 129 0.9× 28 0.5× 7 777

Countries citing papers authored by Jan Fourie

Since Specialization
Citations

This map shows the geographic impact of Jan Fourie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Fourie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Fourie more than expected).

Fields of papers citing papers by Jan Fourie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Fourie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Fourie. The network helps show where Jan Fourie may publish in the future.

Co-authorship network of co-authors of Jan Fourie

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Fourie. A scholar is included among the top collaborators of Jan Fourie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Fourie. Jan Fourie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Lombaard, Johan, Francis Ssali, Thanyawee Puthanakit, et al.. (2021). Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1. Antimicrobial Agents and Chemotherapy. 66(2). e0091621–e0091621. 2 indexed citations
2.
Giaquinto, Carlo, Kulkanya Chokephaibulkit, Marinella Della Negra, et al.. (2017). Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. The Pediatric Infectious Disease Journal. 37(5). 459–465. 9 indexed citations
3.
Lalezari, Jacob, Gulam Latiff, Cynthia Brinson, et al.. (2015). Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. The Lancet HIV. 2(10). e427–e437. 50 indexed citations
4.
Tudor‐Williams, Gareth, Pedro Cahn, Kulkanya Chokephaibulkit, et al.. (2014). Etravirine in treatment‐experienced, HIV‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Medicine. 15(9). 513–524. 19 indexed citations
5.
Antinori, Andrea, Bonaventura Clotet, Jan Fourie, et al.. (2013). Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment‐naïve, HIV‐1‐infected patients at 48 weeks. HIV Medicine. 14(7). 391–400. 33 indexed citations
6.
Cohen, Calvin, Jean‐Michel Molina, Pedro Cahn, et al.. (2012). Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 60(1). 33–42. 130 indexed citations
7.
Fourie, Jan, Jason Flamm, Peré Domingo, et al.. (2011). Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96. HIV Clinical Trials. 12(6). 313–322. 9 indexed citations
8.
Cahn, Pedro, Jan Fourie, Beatriz Grinsztejn, et al.. (2011). Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 25(7). 929–939. 75 indexed citations
9.
Mills, Anthony, Andrea Antinori, Bonaventura Clotet, et al.. (2011). Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks. 1 indexed citations
10.
11.
12.
Cohen, Cal, Jean‐Michel Molina, Pedro Cahn, et al.. (2010). Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients. Journal of the International AIDS Society. 13(S4). 13 indexed citations
13.
Ortiz, Roberto, Edwin DeJesus, Homayoon Khanlou, et al.. (2008). Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 22(12). 1389–1397. 278 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph J. Eron Breakdown of academic impact, for papers by José Valdez Madruga Breakdown of academic impact, for papers by Catherine Granier Breakdown of academic impact, for papers by Dan Duiculescu Breakdown of academic impact, for papers by Christopher Stone Breakdown of academic impact, for papers by Kati Vandermeulen Breakdown of academic impact, for papers by Ellen Koenig Breakdown of academic impact, for papers by Akil Jackson Breakdown of academic impact, for papers by Debbie Hagins Breakdown of academic impact, for papers by Antonio Antela
Rankless by CCL
2026